TotalMarketCap

Apimeds Pharmaceuticals US

APUSNYSE United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$4.049 M

$2.63 -10.10%

Close of 6 Nov 2026

As of 6 Nov 2026, Apimeds Pharmaceuticals US (APUS) has a market capitalization of $4.05M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$6.00M

Loss-making

Shares outstanding

15,091,177

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #457AzitraAZTR$4.43M
  2. #458Xtl BiopharmaceuticalsXTLB$4.22M
  3. #459Apimeds Pharmaceuticals USAPUS$4.05M
  4. #460NuCanaNCNA$3.89M
  5. #461Dermata TherapeuticsDRMA$3.82M

What if Apimeds Pharmaceuticals US were worth as much as…

Open the what-if tool →

Gold $28.2T

$18,304,443

Per share 6,973,121× higher

Bitcoin $1.53T

$990,421.56

Per share 377,303× higher

Apple $5.02T

$3,251,462

Per share 1,238,652× higher

Or at a round number

$5.00M$10.0M$20.0M$50.0M

Where these numbers come from

Share counts and financials for Apimeds Pharmaceuticals US are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.